DrugPatentWatch Database Preview
XADAGO Drug Profile
When do Xadago patents expire, and when can generic versions of Xadago launch?
Xadago is a drug marketed by Us Worldmeds Llc and is included in one NDA. There are three patents protecting this drug.
This drug has ninety patent family members in thirty-one countries.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the safinamide mesylate profile page.
Summary for XADAGO
| International Patents: | 90 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 52 |
| Clinical Trials: | 2 |
| Patent Applications: | 208 |
| Drug Prices: | Drug price information for XADAGO |
| DailyMed Link: | XADAGO at DailyMed |
Generic Entry Opportunity Date for XADAGO
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for XADAGO
| Drug Class | Monoamine Oxidase Type B Inhibitor |
| Mechanism of Action | Monoamine Oxidase-B Inhibitors Breast Cancer Resistance Protein Inhibitors |
Synonyms for XADAGO
| (+-)-(S)-2-((p-((m-Fluorobenzyl)oxy)benzyl)amino)propionamide |
| (2''S'')-2-[[4-[(3-Fluorophenyl)methoxy]phenyl] methylamino]propanamide |
| (2S)-2-[({4-[(3-fluorophenyl)methoxy]phenyl}methyl)amino]propanamide |
| (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide |
| (5)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide |
| (S)-(+)-2-[4-(3-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDE METHANSULFONATE |
| (S)-2-(((4-((3-Fluorophenyl)methoxy)phenyl)methyl)amino)propanamide |
| (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide |
| (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide |
| (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide; compound with methanesulfonic acid |
| (S)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide |
| (S)-2[4-(3-fluorobenzyloxy)benzylamino] propanamide |
| (S)-2[4-(3-fluorobenzyloxy)benzylamino]propanamide |
| 133865-89-1 |
| 2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide |
| 2(s)-(4-(3-fluorobenzyloxy)benzylamino)propionamide |
| 6135AA |
| 90ENL74SIG |
| AC-26829 |
| AC1L2ZLK |
| AJ-112157 |
| AK-77847 |
| AKOS016002015 |
| ANW-58666 |
| API0009223 |
| AX8150732 |
| BC224413 |
| BDBM19187 |
| BDBM50078694 |
| CHEBI:134718 |
| CHEMBL396778 |
| CHEMBL48582 |
| CS-0556 |
| CTK8B7808 |
| D02MOK |
| D0TV6I |
| D10158 |
| DB06654 |
| EC 603-772-2 |
| EMD 1195686 |
| EMD-1195686 |
| Fce 26743 |
| Fce-26743 |
| FT-0700949 |
| GTPL8291 |
| HY-70057 |
| J-506604 |
| M6252 |
| MolPort-005-942-375 |
| N2-(4-((3-Fluorbenzyl)oxy)benzyl)-L-alaninamid |
| N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide |
| NCGC00346529-01 |
| NEMGRZFTLSKBAP-LBPRGKRZSA-N |
| ON 019190.Na |
| P111001 |
| Propanamide, 2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)-, (S)- |
| RL01540 |
| S0935 |
| Safinamide |
| Safinamide (USAN/INN) |
| Safinamide [USAN:INN] |
| safinamide methanesulfonate |
| SAFINAMIDE: - -2-[4- BENZYLAMINO]PROPANAMIDEMETHANSULFONATE |
| SC-89769 |
| SCHEMBL69350 |
| ST24035822 |
| TC-147411 |
| UNII-90ENL74SIG |
| W-5197 |
| ZINC53084692 |
US Patents and Regulatory Information for XADAGO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Us Worldmeds Llc | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Us Worldmeds Llc | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Us Worldmeds Llc | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Us Worldmeds Llc | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for XADAGO
Supplementary Protection Certificates for XADAGO
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015 00042 | Denmark | ➤ Sign Up | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
| 782 | Luxembourg | ➤ Sign Up | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
| 0752 | Netherlands | ➤ Sign Up | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
| 2015 00042 | Denmark | ➤ Sign Up | PRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
